28 results about "Depression model" patented technology

The invention discloses application of traditional Chinese medicine monomer poplar bud flavin (including homologues thereof and extracts / mixtures containing the same) in preparation of drugs for treating nerve injury diseases and a preparation method of the drugs for treating the nerve injury diseases. The pharmacological action mechanism of the monomer poplar bud flavin is deeply explored, and animal model application effect verification proves that the monomer poplar bud flavin (including homologues thereof and extracts / mixtures containing the homologues) can obviously improve core symptoms of cerebral apoplexy, autism, Alzheimer's disease and depression models, is high in safety, and can be used for preparing a medicine for treating cerebral apoplexy, autism, Alzheimer's disease and depression models. The invention also develops a medicine for treating cerebral apoplexy, autism, Alzheimer's disease and depression, which takes the poplatin as a core component (including homologues of the poplatin and extracts / mixtures containing the poplatin), and is expected to provide new research results and application schemes for treatment of nerve injury diseases such as cerebral apoplexy, autism, Alzheimer's disease, depression and the like. The important significance is realized on improving the treatment effect.

The application provides an application of a motion-induced sweat extract in preparation of a medicine for treating, relieving or preventing depression and / or anxiety, and belongs to the field of biological medicine. Specifically, sweat is induced by making a healthy subject perform aerobic exercise of a specific intensity (such as 60%-80% of maximum heart rate), the sweat is collected and eluted by physiological saline, centrifuged and filtered to obtain a biologically active sweat extract. The extract is analyzed by transcriptomics and reverse transcription method to predict the anti-depression potential, and it is proved by in-vivo animal experiments that the extract can significantly improve the anhedonia, behavioral despair and anxiety-like behavior of a depression model mouse, and the effect of a high dose is equivalent to that of a first-line drug fluoxetine. The preparation raw material provided by the application is natural and safe, the preparation process is simple and the cost is low, and a new, easy-to-promote alternative strategy is provided for the prevention and treatment of depression.

The application discloses an application of NOD2 antagonist 1 in preparation of a medicine for preventing or treating depression, and belongs to the technical field of medicines. Specifically, the application relates to an application of a compound NOD2 antagonist 1 in preparation of a medicine for preventing or treating depression. The CAS registration number of the compound NOD2 antagonist 1 is 2411441-54-6. The application discloses a brand-new medicinal use of NOD2 antagonist 1, that is, the compound can be used for preparing a medicine for preventing or treating depression. Animal experiment results show that after intervention of NOD2 antagonist 1, the sucrose preference behavior of a depression model mouse is obviously improved, and depression-related emotional disorder performance is also obviously relieved. Based on the pharmacodynamic verification results, the technical scheme provided by the application has good clinical transformation and popularization and application prospects.

The invention relates to application of broad bean pyrimidine in preparation of antidepressant drugs, and belongs to the technical field of biological medicines. Depression is a common and high-disability heavy mental disorder, has the core characteristics of remarkable and lasting emotion lowering and interest loss, seriously damages the social functions and life quality of patients, and has become one of the major public health burdens in the world. Based on new cognition of complex mechanisms of diseases, a new generation of antidepressant drugs which have a brand new action mechanism, can more accurately intervene in core pathological links of the diseases and can better meet the clinical requirements are researched and developed, and the new generation of antidepressant drugs are not only an inevitable direction for promoting psychopharmacology progress, but also are urgent medical necessities for improving prognosis of hundreds of millions of patients and relieving social burdens. A per2- / -mutant zebrafish depression model is used for performing drug screening on traditional Chinese medicine monomers, and finally it is found that 10 mM of broad bean pyrimidine has the anti-depression characteristic and can effectively improve the depression-like phenotype of per2- / -mutant zebrafish.

The invention relates to the technical field of medicines, and particularly provides application of a 6-(substituted pyridine-4-yl)-5-(substituted phenyl)-1, 2, 4-triazine compound derivative in preparation of an antidepressant drug. A cell experiment proves that the 6-(substituted pyridine-4-yl)-5-(substituted phenyl)-1, 2, 4-triazine compound is an antagonist of an adenosine 2A receptor, and a plurality of animal model experiments prove that the 6-(substituted pyridine-4-yl)-5-(substituted phenyl)-1, 2, 4-triazine compound has a relatively good treatment effect on a plurality of depression models. The compound has an application prospect of being used as an anti-depression treatment drug.

The invention discloses a multi-wavelength laser mode adaptive switching method and system for a depression model, and relates to the technical field of laser adaptive switching. The multi-wavelength laser mode adaptive switching method and system for the depression model comprises the following steps: S1, constructing a multi-source stimulation data set, and performing quality marking and normalization processing; s2, constructing an equipment channel characteristic parameter set, and performing online correction and stability evaluation; s3, generating an equipment compensation stimulation sequence, and performing multi-wavelength laser mode adaptive switching and compensation; and S4, carrying out multi-source stimulation data full-link association and blood relationship management. According to the invention, the consistency of multi-wavelength laser stimulation output among multiple devices and the repeatability of depression model experiment conditions are effectively improved, and the problem that the physical output of the same stimulation scheme on different experiment devices is inconsistent is solved.

The invention discloses a homogeneous polysaccharide from Xiaoyao powder as well as a preparation method and application of the homogeneous polysaccharide. The homogeneous polysaccharide is composed of arabinose, galactose, mannose, glucose and fructose, and the weight-average molecular weight Mw of the homogeneous polysaccharide is 293.223 kDa. The polysaccharide is separated and purified from Xiaoyao powder through water extraction, alcohol precipitation, ion exchange column chromatography, gel column chromatography and other preparation methods. Experimental results show that the homogeneous polysaccharide can improve cortisol-induced zebra fish depression model behavioral performance and improve exercise activity, has anti-depression activity, and can be used for preparing drugs for treating or preventing depression.

The invention relates to an anti-depression compound 4-methyl-6-methoxy coumarin, and belongs to the technical field of biological medicines. Depression is the most common mental disorder in the world and is also a main reason for disability. The development of a novel anti-depression drug which is based on a nerve plasticity mechanism, takes effect quickly, has a lasting curative effect and is high in safety, and particularly has important clinical requirements and technical necessity for an effective treatment means for refractory depression. Traditional Chinese medicine monomers and a per2- / -zebra fish depression model are adopted for anti-depression drug screening, and finally it is found that 10 mM of 4-methyl-6-methoxycoumarin has the anti-depression characteristic and has the positive treatment effect on the exploration behavior, social interaction and sleep-awakening period of per2- / -zebra fish. The method can effectively rescue and reverse depression-like phenotypes observed in a per2- / -zebra fish circadian rhythmic depression model, and can restore the balance of important gene expression.

The invention provides application of Turicibacter sanguinis in preparation of a medicine for preventing and / or treating depression, and belongs to the technical field of biological medicine. Researches find that compared with depression model mice, mice treated by T. sanguinis show significant behavior improvement: sucrose consumption is increased, retention time in an interaction area in a social interaction experiment (a CD1 mouse introduction stage) is prolonged, retention time and total movement distance in a central area in an open field experiment are both increased, and the mice treated by T. sanguinis show significant behavior improvement. And meanwhile, the standing time in a forced swimming experiment is shortened. The results of the behavioral test are consistent to show that the depression-like behavior of the mouse can be obviously alleviated by the T. sanguinis intervention.

The application belongs to the technical field of biological medicine, and relates to a drug for treating depression, and in particular to application of cyclopentolate combined with esketamine in preparation of a drug for treating depression. Experimental researches of the application show that, compared with cyclopentolate or esketamine alone, cyclopentolate combined with esketamine can more significantly improve the depressive behavior of CRS depressive model mice, and it is proved that cyclopentolate combined with esketamine can synergistically enhance the anti-depression effect, so as to be used as a drug for treating depression.

The invention relates to application of 4 '-demethyl epipodophyllotoxin or a medicinal derivative thereof in depression resistance, and belongs to the technical field of biological medicines. Depression is a serious nervous and mental disease and affects millions of people in the world. Major depression is the most common mental disorder and is also one of the main causes of global disability. Depression is considered to be a complex disease caused by interaction of genetic, physiological, psychological and environmental factors. It is found that the novel antidepressant drug capable of treating depression has great significance. A per2- / -mutant zebrafish depression model is utilized to perform drug screening on traditional Chinese medicine monomers, and finally, 10 mu M of 4 '-demethylepipodophyllotoxin has an anti-depression characteristic and can effectively improve the depression-like phenotype of per2- / -mutant zebrafish. A medicinal plant podophyllotoxin from which 4 '-demethyl epipodophyllotoxin is extracted is safe and non-toxic, and no report about 4'-demethyl epipodophyllotoxin depression resistance exists at present.

The invention discloses lactobacillus reuteri FMZ07 and application thereof in depression resistance and intestinal flora improvement, and belongs to the technical field of biomedicine. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC for short), the preservation address is Institute of Microbiology, Chinese Academy of Sciences, No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, the preservation number is CGMCC No.37751, the preservation date is February 9, 2026, and the strain is named as Lactobacillus reuteri in taxonomy. The strain can regulate'microorganism-intestine-brain axis' through multiple targets, the depression-like behavior of depression model mice is remarkably improved, meanwhile, the richness and uniformity of intestinal flora are recovered, and reliable microorganism resources are provided for developing probiotic preparations or drugs for improving depression and assisting improvement of intestinal flora.

This invention discloses the use of silybin derivatives or their stereoisomers, or pharmaceutically acceptable salts, with the structure shown in Formula I in the preparation of medicaments for the prevention and / or treatment of depressive disorders; R1, R2, R3, R4, R5, and R6 are independently selected from hydrogen, methyl, and methyl groups. Compared with silybin alone, royal jelly acid, or a combination of silybin and royal jelly acid, the silybin derivatives of this invention exhibit more significant effects on mouse models of depression induced by chronic social frustration stress and chronic restraint stress, even with significantly reduced dosage, and can be used to prepare medicaments for the treatment of depressive disorders.

The invention discloses an adjustable binding and fixing device for a mouse depression model, and relates to the technical field of experimental animals. Comprising a containing pipe, a conical head is arranged at one end of the containing pipe, a plurality of ventilation holes are formed in the conical head, a longitudinal opening is formed in the pipe wall of the containing pipe, one end of the longitudinal opening extends to the end, away from the conical head, of the containing pipe, and the other end of the longitudinal opening extends to one side of the conical head; the inner diameter of the adjustable restraining piece is matched with the outer diameter of the containing pipe, the adjustable restraining piece is detachably installed on the outer side of the containing pipe, the adjustable restraining piece is of a C-shaped structure, connecting pieces are integrally arranged at the two ends of the adjustable restraining piece, and adjusting parts are arranged on the connecting pieces. Through the cooperative design of the C-shaped adjustable restraining piece and the adjusting screw, continuous adjustment of the inner diameter of the containing pipe is achieved, the device is suitable for laboratory mice of different body types, precise adaptation of the mouse body types is achieved, and restraining effectiveness and safety are ensured.

The application discloses application of hippuric acid in preparation of a medicine for preventing and / or treating depression, and belongs to the technical field of biological medicine. The hippuric acid or pharmaceutically acceptable salt thereof has significant and multi-target antidepressant pharmacological activity through chronic mild stress depression animal model experiment. Specifically, in terms of improving core depressive symptoms, the sugar water preference experiment result shows that the hippuric acid can effectively reverse CUMS-induced hedonic deficiency of mice, and significantly improves the sucrose preference rate, and the forced swimming experiment proves that the hippuric acid can significantly shorten the immobility time of mice and relieve behavioral despair; in terms of improving anxiety-like behavior, the mine field experiment data show that after the hippuric acid intervention, the number of times of entering the central area, the residence time and the total activity distance of the depressive model mice are all significantly increased, which indicates that the hippuric acid can effectively improve the spontaneous activity reduction caused by chronic stress.

The invention relates to a method for high-throughput screening of antidepressant drugs and application of pectolinarin in depression resistance, and belongs to the technical field of biological medicines. Depression is a serious neurological and mental disease and affects millions of people in the world. Major depression is one of common mental diseases and is also one of main reasons causing global disability. It is found that the new antidepressant drug capable of treating depression has important significance. According to the application, firstly, an animal model, namely, a per2- / -mutant zebrafish depression model, capable of realizing high-throughput screening of antidepressant drugs is constructed, secondly, the model is used for drug screening of traditional Chinese medicine monomers, and finally, it is found that 10 mu M of pectolinarin can effectively rescue depression-like phenotypes of per2- / -mutant zebrafish. A new strategy is provided for precise treatment of depression, a potential pharmacological mechanism of depression is researched, and an effective means is expected to be provided for clinical treatment of depression.

The application relates to the field of biomedical technology, in particular to a method for analyzing lipid spatial metabolism of whole brain tissue of ELS-induced depression-like behavior rats, which comprises the following steps: first, an ELS-induced depression-like behavior rat model is constructed, and a depression model group is determined by adopting a depression-like behavior test; then, a conventional rat is taken as a control group, 2D scanning is carried out on the control group and the depression model group based on mass spectrometry spatial omics technology, 2D brain lipid maps are constructed, and whole brain 3D reconstruction is carried out to obtain brain tissue lipid mass spectrometry imaging data; finally, metabolic heterogeneity analysis is carried out on the brain tissue lipid mass spectrometry imaging data. The method provided by the application aims to provide technical and data atlas support for the research on the molecular mechanism of lipid metabolism disorder in the occurrence and development of early negative stress-induced depression from the animal model level, and simultaneously expands the application range of mass spectrometry spatial omics technology.

The application belongs to the field of medicine and relates to application of an isoflavone compound, isoformononetin (IFM), in preparation of a medicine or health care product for preventing and treating depression; in mouse hippocampal neuron cells (HT22) or mouse microglial cells (BV2), IFM can reduce neuroinflammation caused by corticosterone (CORT) or lipopolysaccharide (LPS) and increase the expression level of brain-derived neurotrophic factor (BDNF); in a chronic mild unpredictable stress mouse depression model, IFM can relieve depression-like behavior of the mouse and reduce the inflammation level of brain tissue, indicating that IFM has a good effect of relieving depression; IFM degrades PDE4D protein by directly combining with a PDE4D target protein. The isoflavone compound IFM has the advantages of outstanding effect and high safety and is expected to develop into an effective medicine for treating and preventing depression.

This invention discloses the application of a natural isoflavone compound in the preparation of drugs for the prevention or treatment of depression. The natural isoflavone compound is hematoxylin A, a derivative of hematoxylin A, or a pharmaceutically acceptable salt of hematoxylin A. Hematoxylin A can effectively reduce oxidative damage to HT22 neurons in the hippocampus induced by glutamate and corticosterone, and can significantly improve the behavioral performance of mice in a chronic restraint stress depression model, exhibiting clear antidepressant activity. Hematoxylin A has a well-defined structure and good safety profile, showing promising application prospects in the development of antidepressant drugs.

The invention relates to application of lycorine and derivatives thereof in preparation of antidepressant drugs, and belongs to the technical field of biological medicines. According to the application disclosed by the invention, a drug compound library is screened by utilizing a per2- / -mutant zebrafish depression model, and the situation that 10 mu M of lycorine chloride can effectively rescue the depression-like phenotype of the per2- / -mutant zebrafish is found; the monomer shows remarkable treatment effects in a per2 gene knockout zebrafish depression model: (1) behavioral improvement: depression-like phenotypes such as per2- / -zebrafish exploration behavior reduction, social interaction defects and sleep-awakening rhythm disorder can be effectively reversed; (2) molecular mechanism regulation: restoring neurotransmitter steady state by down-regulating cortisol level and inflammation-related gene expression; lycorine chloride comes from plants, is easy to obtain and low in cost, and can be combined with existing western medicines in the market to treat depression, so that depression symptoms can be relieved.

The invention belongs to the technical field of biological medicine, and particularly relates to a TRPML1 specific small molecule agonist ML-SA5 and application thereof. The structural formula of the TRPML1 specific small molecule agonist ML-SA5 is as shown in the specification. The TRPML1 specific micromolecule agonist ML-SA5 has the beneficial effects that the TRPML1 specific micromolecule agonist ML-SA5 can be used for remarkably reducing the central nervous inflammation level of a depression model mouse; the mouse neuron excitability of the depression model is improved; depression-like behaviors of depression model mice are improved; the brain function of a depression model mouse is comprehensively protected; the TRPML1 specific micromolecule agonist ML-SA5 provided by the invention provides a new medicine for treating depression, and has good market value and clinical application prospect.

The invention provides application of diethyl phthalate (DEP) in an induced zebra fish depression model, and belongs to the technical field of animal models. The preparation method comprises the following steps: firstly dissolving a diethyl phthalate solution in DMSO (Dimethylsulfoxide), and then mixing with water to obtain diethyl phthalate feeding water; putting zebra fish into the diethyl phthalate feeding water for feeding; the depression-like phenotype of the zebra fish is confirmed through behavioral testing. The method is simple and convenient to operate, the constructed model can stably reproduce DEP-induced behaviors and molecular level changes, and the method is suitable for plasticizer toxicology screening and depression pathogenesis research; and an economic and efficient research tool capable of replacing mammalian experiments is provided for safety evaluation of DEP and research and development of nervous system drugs.

The invention discloses an application of a medicine for relieving senile depression and a verification method of the medicine, and relates to a new application of Ro61-8048 in preparation of the medicine for relieving the senile depression, and provides a verification method based on a chronic unpredictable mild stress (CUMS) model of a 18-month-old C57BL / 6J mouse. Six behavioral indexes of sucrose preference, open field, new object recognition, Y maze, forced swimming and social interaction prove that by intraperitoneal administration of 50 mg / kg Ro61-8048, low emotion, anxiety level rise and cognitive impairment of an old depression model mouse can be remarkably reversed, the curative effect is equivalent to that of a classic antidepressant fluoxetine hydrochloride (20 mg / kg), and no obvious side effect is caused to normal old mice. The invention provides an experimental basis and a drug effect evaluation platform for taking the KMO inhibitor as a novel treatment strategy of the LLD.

This invention belongs to the field of traditional Chinese medicine and natural product technology, specifically relating to the use of Leonurus japonicus extract in the preparation of antidepressant drugs. This invention uses 70% ethanol extraction to prepare Leonurus japonicus extract. This extraction method reduces extraction costs, shortens production time, increases extract yield, increases the extraction rate of effective components, and increases enterprise production efficiency. This invention also uses multiple depression models to verify the antidepressant activity of Leonurus japonicus extract, including a chronic unpredictable mild stress-induced depression model, a chronic corticosterone injection-induced depression model, and an ovariectomy combined with hormone withdrawal-induced depression model. The results show that Leonurus japonicus extract has a significant antidepressant effect in experimental animals. The antidepressant effect of the Leonurus japonicus extract of this invention is not obvious compared to the characteristics of traditional gynecological drugs, and it focuses on hormone-related depression, demonstrating the therapeutic value of Leonurus japonicus extract in the clinical classification of depression.

The invention relates to the technical field of medicines, in particular to an application of Neoline in quickly taking effect and resisting depression. The C19 type diterpenoid alkaloid Neoline provided by the invention shows remarkable and quick-acting anti-depression activity in both a corticosterone-induced mouse depression model and a chronic constraint stress mouse depression model, the drug effect is equivalent to that of a positive drug esketamine ((S)-Ketamine), but the effective dose is far lower than that of the positive drug (S)-Ketamine, and the C19 type diterpenoid alkaloid Neoline can be orally taken, so that the C19 type diterpenoid alkaloid Neoline can be used for treating depression. The medicine compliance and usability are better, and the compound can be used for developing anti-depression medicines which take effect quickly.

The application provides a traditional Chinese medicine composition for treating depression and application thereof, and relates to the technical field of traditional Chinese medicine pharmacy; the traditional Chinese medicine composition is composed of ten traditional Chinese medicines, namely, flowers of Chinese sweet gum, white daphne, cyperus rotundus, lycium ruthenicifolium, citrus medica, seven mile incense, saussurea lappa, zanthoxylum arms, radix zanthoxyli and lignum aquilariae resiniferum, and the combined use of the medicines has the effects of soothing liver and relieving depression and regulating and smoothing qi movement; the traditional Chinese medicine composition can improve the depressive behavior of a mouse with depression, significantly reduces the levels of inflammatory related factors IL-6, IL-1beta and TNF-alpha in serum of a mouse model with depression, and obviously improves the levels of monamine neurotransmitters 5-HT, DA and NE of the mouse; the traditional Chinese medicine composition can significantly reduce the HAMD score, PSQI score and TCM syndrome integral of a patient with depression, has a high total effective rate for treating depression, and provides a traditional Chinese medicine composition with remarkable effect and no toxic side effect for treating depression.

The invention belongs to the technical field of application of natural medicines, and particularly discloses application of SSK-9-1 in preparation of medicines for preventing or treating depression and anxiety. Animal behavioral experiments prove that SSK-9-1 shows a positive improvement effect on depression and anxiety behaviors of a depression model mouse, and the exploration behavior and interest level of the mouse in a new environment can be improved. Specifically, in an open field experiment, SSK-9-1 can significantly prolong the residence time of a depression mouse in a central area and increase the number of times of entering the central area; in an elevated cross maze experiment, the SSK-9-1 can obviously increase the number of times that a depression mouse enters an open arm and the staying time of the depression mouse in a target area. SSK-9-1 provides a new thought and basis for developing natural medicines to prevent or treat depression and anxiety, and has a good application prospect.

The invention relates to an application of a traditional Chinese medicine composition in preparation of a medicament for treating depression, which is characterized in that the traditional Chinese medicine composition is prepared from ginseng, rehmannia, cistanche, salvia miltiorrhiza, polygala tenuifolia, rhizoma acori graminei and curcuma aromatica. The composition can obviously improve the depression-like behavior of a depression model mouse, improve the level of nutritional factors in the brain of the depression model mouse and reduce the level of pro-inflammatory cytokines of the depression model mouse, and has a good treatment effect on depression.